Lataa...

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Komarova, Natalia L., Burger, Jan A., Wodarz, Dominik
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: National Academy of Sciences 2014
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4183279/
https://ncbi.nlm.nih.gov/pubmed/25201956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1409362111
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!